Cargando…

Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population

PURPOSE: We aimed to assess the efficacy of the Jiang Tang San Huang (JTSH) tablet for the treatment of patients with type 2 diabetes mellitus (T2DM). METHODS: All data for this retrospective cohort study were acquired from the outpatient clinic database of our institution, and all enrolled patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Cui, Sun, Mengxue, Liu, Wanwen, Zhao, Shaoyang, Liu, Yang, Chen, Yuna, Liang, Shu-Nung, Yuan, Haoyu, Sui, Huacheng, Wang, Baohua, Li, Saimei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793732/
https://www.ncbi.nlm.nih.gov/pubmed/36582504
http://dx.doi.org/10.2147/DMSO.S388336
_version_ 1784859896184832000
author Shao, Cui
Sun, Mengxue
Liu, Wanwen
Zhao, Shaoyang
Liu, Yang
Chen, Yuna
Liang, Shu-Nung
Yuan, Haoyu
Sui, Huacheng
Wang, Baohua
Li, Saimei
author_facet Shao, Cui
Sun, Mengxue
Liu, Wanwen
Zhao, Shaoyang
Liu, Yang
Chen, Yuna
Liang, Shu-Nung
Yuan, Haoyu
Sui, Huacheng
Wang, Baohua
Li, Saimei
author_sort Shao, Cui
collection PubMed
description PURPOSE: We aimed to assess the efficacy of the Jiang Tang San Huang (JTSH) tablet for the treatment of patients with type 2 diabetes mellitus (T2DM). METHODS: All data for this retrospective cohort study were acquired from the outpatient clinic database of our institution, and all enrolled patients received JTSH tablet for at least two months. Overall, 147 patients were included in the analysis. The primary outcome was patient-reported outcomes on the efficacy of the JTSH tablets using a questionnaire survey. Correlation analysis evaluated the duration of JTSH tablet administration and glycemic control in patients with T2DM. The secondary outcome measures included: changes in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial blood glucose, homeostasis model assessment of insulin resistance index (HOMA-IR) and homeostasis model assessment of β-cell function (HOMA-β) after 2 months of treatment with JTSH tablets. RESULTS: Overall,120 patients (81.63%) reported a JTSH tablet treatment satisfaction score of ≥60 points, and believed that JTSH tablets had satisfactory hypoglycemic effects and could improve symptoms. The average duration of JTSH tablet treatment was 2.57±1.45 years. Overall, 111 patients achieved good blood glucose control, while 36 patients had poor glycemic control. Multivariate logistic regression model analysis showed that taking JTSH tablets for 1 year might reduce the risk of poor hypoglycemic effect by 17.00% (Risk ratio=0.830, 95% confidence interval:0.578, 1.021, P=0.066). Compared with the baseline data, the levels of HbA1c, FPG and HOMA-IR decreased significantly and HOMA-β levels increased significantly (P<0.05). CONCLUSION: Good blood glucose control may be positively correlated with the duration of JTSH tablets administration. Patients with T2DM were satisfied with the anti-diabetic effects of JTSH tablets, which can significantly reduce blood glucose and insulin resistance, and improve the function of islet cells.
format Online
Article
Text
id pubmed-9793732
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97937322022-12-28 Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population Shao, Cui Sun, Mengxue Liu, Wanwen Zhao, Shaoyang Liu, Yang Chen, Yuna Liang, Shu-Nung Yuan, Haoyu Sui, Huacheng Wang, Baohua Li, Saimei Diabetes Metab Syndr Obes Original Research PURPOSE: We aimed to assess the efficacy of the Jiang Tang San Huang (JTSH) tablet for the treatment of patients with type 2 diabetes mellitus (T2DM). METHODS: All data for this retrospective cohort study were acquired from the outpatient clinic database of our institution, and all enrolled patients received JTSH tablet for at least two months. Overall, 147 patients were included in the analysis. The primary outcome was patient-reported outcomes on the efficacy of the JTSH tablets using a questionnaire survey. Correlation analysis evaluated the duration of JTSH tablet administration and glycemic control in patients with T2DM. The secondary outcome measures included: changes in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2-hour postprandial blood glucose, homeostasis model assessment of insulin resistance index (HOMA-IR) and homeostasis model assessment of β-cell function (HOMA-β) after 2 months of treatment with JTSH tablets. RESULTS: Overall,120 patients (81.63%) reported a JTSH tablet treatment satisfaction score of ≥60 points, and believed that JTSH tablets had satisfactory hypoglycemic effects and could improve symptoms. The average duration of JTSH tablet treatment was 2.57±1.45 years. Overall, 111 patients achieved good blood glucose control, while 36 patients had poor glycemic control. Multivariate logistic regression model analysis showed that taking JTSH tablets for 1 year might reduce the risk of poor hypoglycemic effect by 17.00% (Risk ratio=0.830, 95% confidence interval:0.578, 1.021, P=0.066). Compared with the baseline data, the levels of HbA1c, FPG and HOMA-IR decreased significantly and HOMA-β levels increased significantly (P<0.05). CONCLUSION: Good blood glucose control may be positively correlated with the duration of JTSH tablets administration. Patients with T2DM were satisfied with the anti-diabetic effects of JTSH tablets, which can significantly reduce blood glucose and insulin resistance, and improve the function of islet cells. Dove 2022-12-23 /pmc/articles/PMC9793732/ /pubmed/36582504 http://dx.doi.org/10.2147/DMSO.S388336 Text en © 2022 Shao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Shao, Cui
Sun, Mengxue
Liu, Wanwen
Zhao, Shaoyang
Liu, Yang
Chen, Yuna
Liang, Shu-Nung
Yuan, Haoyu
Sui, Huacheng
Wang, Baohua
Li, Saimei
Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population
title Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population
title_full Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population
title_fullStr Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population
title_full_unstemmed Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population
title_short Patient-Reported Outcomes Following the Use of Jiang Tang San Huang Tablets in Type 2 Diabetes Mellitus: A Retrospective Cohort Study in a Chinese Population
title_sort patient-reported outcomes following the use of jiang tang san huang tablets in type 2 diabetes mellitus: a retrospective cohort study in a chinese population
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793732/
https://www.ncbi.nlm.nih.gov/pubmed/36582504
http://dx.doi.org/10.2147/DMSO.S388336
work_keys_str_mv AT shaocui patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT sunmengxue patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT liuwanwen patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT zhaoshaoyang patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT liuyang patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT chenyuna patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT liangshunung patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT yuanhaoyu patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT suihuacheng patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT wangbaohua patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation
AT lisaimei patientreportedoutcomesfollowingtheuseofjiangtangsanhuangtabletsintype2diabetesmellitusaretrospectivecohortstudyinachinesepopulation